Table 1 Characteristics of COVID-19 ARDS
All patients (n = 179) | Prophylactic Group (n = 108) | Therapeutic Group (n = 71) | p | |
|---|---|---|---|---|
Age—median, IQR | 62 [51; 70] | 61 [51; 70] | 64 [53; 71] | 0.56 |
Male—n (%) | 130 (72.6) | 83 (76.9) | 47 (66.2) | 0.12 |
BMI (kg/m2)—median, IQR | 30 [26; 34] | 29 [26; 33] | 31 [27; 34] | 0.25 |
Medical history—n (%) | ||||
Malignancies/hemopathies | 8 (4.5) | 4 (3.7) | 4 (5.6) | 0.79 |
Cardiovascular diseases | 76 (42.4) | 43 (39.8) | 33 (46.5) | 0.38 |
Thrombo-embolic event | 9 (5.0) | 7 (6.5) | 2 (2.8) | 0.46 |
Cerebrovascular diseases | 7 (3.9) | 3 (2.8) | 4 (5.6) | 0.56 |
Immune diseases | 2 (1.1) | 2 (1.9) | 0 (0.0) | 0.73 |
Diabetes | 31 (17.3) | 13 (12.0) | 18 (25.3) | 0.02 |
Chronic liver disease | 3 (1.7) | 2 (1.9) | 1 (1.4) | 1 |
Chronic renal disease | 16 (8.9) | 5 (4.6) | 11 (15.5) | 0.02 |
Respiratory disease | 20 (11.2) | 12 (11.1) | 8 (11.3) | 0.97 |
Baseline severity scores | ||||
SAPS II—median, IQR | 47 [37; 63] | 48 [37; 63] | 47 [38; 62] | 0.72 |
SOFA—median, IQR | 8 [5; 10] | 8 [5; 10] | 8 [5; 10] | 0.90 |
Anticoagulation treatment in ICU | ||||
LMWH—n (%) | 115 (64.2) | 87 (80.6) | 28 (39.4) | < 0.05 |
UFH—n (%) | 64 (35.8) | 21 (19.4) | 43 (60.6) | < 0.05 |
Supportive treatments | ||||
Invasive mechanical ventilation—n (%) | 179 (100) | 108 (100) | 71 (100) | 1 |
RRT—n (%) | 35 (19.6) | 16 (14.8) | 19 (26.8) | 0.05 |
ECMO—n (%) | 11 (6.2) | 5 (4.6) | 6 (8.5) | 0.47 |
ECMO duration (days)—median, IQR | 7.0 [6.5; 11.0] | 7.0 [7.0; 11.0] | 8.0 [6.3; 10.5] | 1 |
Outcome | ||||
ICU length of stay (days)—median, IQR | 10 [5; 19] | 9 [5; 18] | 10 [6; 19] | 0.27 |
ICU mortality—n (%) | 31 (17.3) | 20 (18.5) | 11 (15.5) | 0.67 |